17:59 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Valneva reports Phase I data for Lyme disease vaccine candidate

Valneva SE (Euronext Paris:VLA; VSE:VLA) reported interim data from a Phase I trial in 179 healthy volunteers ages 18-40 showing that Lyme disease candidate VLA15 (VLA15-101) met the primary endpoint by achieving a "favorable" safety...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
19:03 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Sanofi discontinues C. difficile vaccine

Sanofi (Euronext:SAN; NYSE:SNY) discontinued development of its late-stage...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
22:37 , Apr 19, 2017 |  BC Extra  |  Company News

Management tracks

Cardiovascular company MyoKardia Inc. (NASDAQ:MYOK) appointed David Meeker to its board. He is stepping down at the end of June as EVP and general manager of the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Immunotherapy company...
16:00 , Mar 10, 2017 |  BC Extra  |  Company News

Management tracks

Orphan disease company Dynacure S.A.S. (Illkirch-Graffenstaden, France) named Stephane van Rooijen CEO and Frederic Legros COO. van Rooijen was CEO at Confo Therapeutics N.V. (Brussels, Belgium). Legros was VP and corporate head of business development...
20:31 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Valneva completes private placement

Valneva raised €7.5 million ($7.9 million) through the sale of 2.9 million shares at €2.60 in a private placement with MVM Life Science Partners. Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France ...
22:11 , Dec 13, 2016 |  BC Week In Review  |  Clinical News

VLA15-101: Ph I started

Valneva began a single-blind, dose-escalation, international Phase I trial to evaluate VLA15-101 in about 180 healthy volunteers. Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France  Product: VLA15-101  Business: Infectious  Molecular target: Borrelia outer surface protein A (ospA)...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipoteichoic acid (LTA); heparin-binding EGF-like growth factor (HBEGF; DTR)

Infectious disease INDICATION: Clostridium Mouse studies suggest LTA glycan-based vaccines could help prevent Clostridium difficile infection (CDI). In a mouse challenge model of CDI, a compound composed of glycans from C. difficile LTA conjugated to...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

Valneva financial update

Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France   Business: Antibodies, Infectious, Gastrointestinal   Date announced: 2016-07-12   Note: Valneva secured a five-year, EUR25 million ($27.6 million) loan facility from the European Investment Bank (EIB). The loan...